Research suggests that the T7 peptide can enhance the accumulation of shRNA in the brain, thereby mediating the downregulation of vascular endothelial growth factor (VEGF), with the aim of treating GBM (Kuang et al., 2016). This evidence concerns the gene VEGFA and glioblastoma.